World Health Organization Sounds Concern Over Acute Scarcity of Obesity Injections
Under one in 10 patients who could benefit from weight-loss injections like Wegovy are able to get them, states the global health agency as it publishes its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is urging broader and more equitable availability to this class of drugs.
According to forecasts, over two billion could be obese by 2030 if no action is taken.
"The latest guidance affirms that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are major hurdles to universal availability to the treatments that can aid individuals in losing significant body mass, says the body.
Skinny Jab Supply Crisis
Despite the current most optimistic case, the manufacturing of these medications might only reach approximately 100 million people – under 10% of the global need, according to the health organization.
The advice encourages governments and firms to expand availability, through strategies like patent sharing.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Injections Operate
These medications replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so users eat less.
Patients commonly see weight reduction in the initial weeks of commencing the regular doses.
Research points to users may put most of the weight back on within a year of halting the medication, when their usual hunger come back.
To be carrying excess weight elevates your risk for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns people in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
